These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 35567345)

  • 21. Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy.
    Mercuri E; Darras BT; Chiriboga CA; Day JW; Campbell C; Connolly AM; Iannaccone ST; Kirschner J; Kuntz NL; Saito K; Shieh PB; Tulinius M; Mazzone ES; Montes J; Bishop KM; Yang Q; Foster R; Gheuens S; Bennett CF; Farwell W; Schneider E; De Vivo DC; Finkel RS;
    N Engl J Med; 2018 Feb; 378(7):625-635. PubMed ID: 29443664
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of infantile-onset spinal muscular atrophy with nusinersen: final report of a phase 2, open-label, multicentre, dose-escalation study.
    Finkel RS; Chiriboga CA; Vajsar J; Day JW; Montes J; De Vivo DC; Bishop KM; Foster R; Liu Y; Ramirez-Schrempp D; Schneider E; Bennett CF; Wong J; Farwell W
    Lancet Child Adolesc Health; 2021 Jul; 5(7):491-500. PubMed ID: 34089650
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of real-life outcome data of patients with spinal muscular atrophy treated with nusinersen in Switzerland.
    Tscherter A; Rüsch CT; Baumann D; Enzmann C; Hasselmann O; Jacquier D; Jung HH; Kruijshaar ME; Kuehni CE; Neuwirth C; Stettner GM; Klein A;
    Neuromuscul Disord; 2022 May; 32(5):399-409. PubMed ID: 35337708
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gene replacement therapy with onasemnogene abeparvovec in children with spinal muscular atrophy aged 24 months or younger and bodyweight up to 15 kg: an observational cohort study.
    Weiß C; Ziegler A; Becker LL; Johannsen J; Brennenstuhl H; Schreiber G; Flotats-Bastardas M; Stoltenburg C; Hartmann H; Illsinger S; Denecke J; Pechmann A; Müller-Felber W; Vill K; Blaschek A; Smitka M; van der Stam L; Weiss K; Winter B; Goldhahn K; Plecko B; Horber V; Bernert G; Husain RA; Rauscher C; Trollmann R; Garbade SF; Hahn A; von der Hagen M; Kaindl AM
    Lancet Child Adolesc Health; 2022 Jan; 6(1):17-27. PubMed ID: 34756190
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy.
    Finkel RS; Mercuri E; Darras BT; Connolly AM; Kuntz NL; Kirschner J; Chiriboga CA; Saito K; Servais L; Tizzano E; Topaloglu H; Tulinius M; Montes J; Glanzman AM; Bishop K; Zhong ZJ; Gheuens S; Bennett CF; Schneider E; Farwell W; De Vivo DC;
    N Engl J Med; 2017 Nov; 377(18):1723-1732. PubMed ID: 29091570
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Population Pharmacokinetics of Nusinersen in the Cerebral Spinal Fluid and Plasma of Pediatric Patients With Spinal Muscular Atrophy Following Intrathecal Administrations.
    Luu KT; Norris DA; Gunawan R; Henry S; Geary R; Wang Y
    J Clin Pharmacol; 2017 Aug; 57(8):1031-1041. PubMed ID: 28369979
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Effect of Nusinersen Therapy on Laboratory Parameters of Patients with Spinal Muscular Atrophy.
    Sarıkaya Uzan G; Paketçi C; Günay Ç; Edem P; Özsoy Ö; Hız Kurul S; Yiş U
    Neuropediatrics; 2022 Oct; 53(5):321-329. PubMed ID: 35871521
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neurofilament Levels in CSF and Serum in an Adult SMA Cohort Treated with Nusinersen.
    Rich KA; Fox A; Yalvac M; Heintzman S; Tellez M; Bartlett A; Severyn S; Linsenmayer M; Kelly K; Reynolds J; Sterling GB; Weaver T; Rajneesh K; Pino MG; Arnold WD; Elsheikh B; Kolb SJ
    J Neuromuscul Dis; 2022; 9(1):111-119. PubMed ID: 34776417
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nusinersen for Spinal Muscular Atrophy in the United States: Findings From a Retrospective Claims Database Analysis.
    Gauthier-Loiselle M; Cloutier M; Toro W; Patel A; Shi S; Davidson M; Bischof M; LaMarca N; Dabbous O
    Adv Ther; 2021 Dec; 38(12):5809-5828. PubMed ID: 34713391
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Feeding and Swallowing Problems in Infants with Spinal Muscular Atrophy Type 1: an Observational Study.
    van der Heul AMB; Cuppen I; Wadman RI; Asselman F; Schoenmakers MAGC; van de Woude DR; Gerrits E; van der Pol WL; van den Engel-Hoek L
    J Neuromuscul Dis; 2020; 7(3):323-330. PubMed ID: 32333596
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nusinersen in later-onset spinal muscular atrophy: Long-term results from the phase 1/2 studies.
    Darras BT; Chiriboga CA; Iannaccone ST; Swoboda KJ; Montes J; Mignon L; Xia S; Bennett CF; Bishop KM; Shefner JM; Green AM; Sun P; Bhan I; Gheuens S; Schneider E; Farwell W; De Vivo DC;
    Neurology; 2019 May; 92(21):e2492-e2506. PubMed ID: 31019106
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Real-World Data from Nusinersen Treatment for Patients with Later-Onset Spinal Muscular Atrophy: A Single Center Experience.
    Mendonça RH; Polido GJ; Matsui C; Silva AMS; Solla DJF; Reed UC; Zanoteli E
    J Neuromuscul Dis; 2021; 8(1):101-108. PubMed ID: 33074187
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nusinersen Modulates Proteomics Profiles of Cerebrospinal Fluid in Spinal Muscular Atrophy Type 1 Patients.
    Bianchi L; Sframeli M; Vantaggiato L; Vita GL; Ciranni A; Polito F; Oteri R; Gitto E; Di Giuseppe F; Angelucci S; Versaci A; Messina S; Vita G; Bini L; Aguennouz M
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33919289
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluator Training and Reliability for SMA Global Nusinersen Trials1.
    Glanzman AM; Mazzone ES; Young SD; Gee R; Rose K; Mayhew A; Nelson L; Yun C; Alexander K; Darras BT; Zolkipli-Cunningham Z; Tennekoon G; Day JW; Finkel RS; Mercuri E; De Vivo DC; Baldwin R; Bishop KM; Montes J
    J Neuromuscul Dis; 2018; 5(2):159-166. PubMed ID: 29865090
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neurofilament light chain in serum of adolescent and adult SMA patients under treatment with nusinersen.
    Wurster CD; Steinacker P; Günther R; Koch JC; Lingor P; Uzelac Z; Witzel S; Wollinsky K; Winter B; Osmanovic A; Schreiber-Katz O; Al Shweiki R; Ludolph AC; Petri S; Hermann A; Otto M;
    J Neurol; 2020 Jan; 267(1):36-44. PubMed ID: 31552549
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nusinersen in adults with 5q spinal muscular atrophy: a non-interventional, multicentre, observational cohort study.
    Hagenacker T; Wurster CD; Günther R; Schreiber-Katz O; Osmanovic A; Petri S; Weiler M; Ziegler A; Kuttler J; Koch JC; Schneider I; Wunderlich G; Schloss N; Lehmann HC; Cordts I; Deschauer M; Lingor P; Kamm C; Stolte B; Pietruck L; Totzeck A; Kizina K; Mönninghoff C; von Velsen O; Ose C; Reichmann H; Forsting M; Pechmann A; Kirschner J; Ludolph AC; Hermann A; Kleinschnitz C
    Lancet Neurol; 2020 Apr; 19(4):317-325. PubMed ID: 32199097
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy of nusinersen in type 1, 2 and 3 spinal muscular atrophy: Real world data from Hungarian patients.
    Szabó L; Gergely A; Jakus R; Fogarasi A; Grosz Z; Molnár MJ; Andor I; Schulcz O; Goschler Á; Medveczky E; Czövek D; Herczegfalvi Á
    Eur J Paediatr Neurol; 2020 Jul; 27():37-42. PubMed ID: 32456992
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of putative CSF biomarkers in paediatric spinal muscular atrophy (SMA) patients before and during treatment with nusinersen.
    Johannsen J; Weiss D; Daubmann A; Schmitz L; Denecke J
    J Cell Mol Med; 2021 Sep; 25(17):8419-8431. PubMed ID: 34312963
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nusinersen in type 1 SMA infants, children and young adults: Preliminary results on motor function.
    Pane M; Palermo C; Messina S; Sansone VA; Bruno C; Catteruccia M; Sframeli M; Albamonte E; Pedemonte M; D'Amico A; Brigati G; de Sanctis R; Coratti G; Lucibello S; Bertini E; Vita G; Tiziano FD; Mercuri E;
    Neuromuscul Disord; 2018 Jul; 28(7):582-585. PubMed ID: 29960818
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical Outcomes in Patients with Spinal Muscular Atrophy Type 1 Treated with Nusinersen.
    de Holanda Mendonça R; Jorge Polido G; Ciro M; Jorge Fontoura Solla D; Conti Reed U; Zanoteli E
    J Neuromuscul Dis; 2021; 8(2):217-224. PubMed ID: 33459657
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.